首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1830996

血漿治療市場

Plasma Therapy Market

出版日期: 2025年09月24日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

血漿療法市場預計將從 2024 年的 5.4017 億美元擴大到 2031 年的 13.0843 億美元，2025 年至 2031 年的複合年成長率預計為 13.80%。

分析師的觀點

血漿療法市場分析突顯了以下關鍵成長因素：骨科疾病盛行率不斷上升，尤其是在老年人群體中；運動員關節和肌肉損傷的增加；以及對微創美容治療的需求不斷成長。此外，根據患者個別需求客製化血漿療法的能力預計將在2022年至2030年期間引領市場新趨勢。

血漿療法，也稱為富血小板血漿 (PRP) 療法，是指使用康復患者的血漿來治療各種疾病並促進癒合。 PRP 療法在骨科中用於關節損傷，在皮膚科用於皮膚再生，在牙科用於組織修復。 PRP 中的生長因子可有效刺激組織再生，加速損傷癒合並增強美容效果。

市場洞察骨科疾病和肌肉損傷發病率的不斷上升以及 PRP 在美容治療中的應用日益廣泛推動了血漿療法市場的發展根據世界衛生組織 (WHO) 於 2023 年發布的資料，2019 年全球約有 5.28 億人患有骨關節炎 (OA)，自 1990 年以來成長了 113%。 PubMed Central 2020 年 12 月的一篇文章指出，PRP 因其富含生長因子和細胞因子而具有巨大的組織修復潛力，這些生長因子和細胞因子對於創造和調節軟組織和硬組織的再生環境至關重要。 PRP 療法有助於骨折、韌帶、肌肉和肌腱損傷、周邊神經損傷、關節軟骨病變和骨關節炎的癒合。因此，骨科和組織修復應用對血漿療法的需求強勁。

此外，PRP 在美容手術中的應用日益廣泛，包括皮膚再生、抗衰老和其他美容應用。 2021 年 11 月發表於 PubMed Central 的一篇綜述評估了 73 項研究，其中 45 項研究了 PRP 單藥治療，35 項研究了 PRP 與微針療法的聯合應用。這些療法通常耐受性良好，且對各種膚質均有效。據報道，PRP 在皮膚再生、疤痕修復、脫髮、色素沉著、硬化性苔蘚、麻風病引起的周邊神經病變、斑塊狀乾癬和指甲疾病等疾病方面均取得了積極成果。

因此，PRP 在美容手術中的應用對血漿療法市場的成長做出了重大貢獻。

未來趨勢血漿治療市場中以患者為中心的治療客製化選項的出現客製化血漿治療涉及根據患者的醫療狀況和基因特徵客製化治療方案以滿足患者的特定需求。這些客製化工作旨在透過調整抗體和蛋白質等成分的組成來提高血漿治療的有效性，從而更好地解決患者的健康問題。研究人員和醫療保健專業人員正在努力針對自體免疫疾病、傳染病和罕見癌症等特定疾病開發客製化的血漿療法。 Regenexx 和 Bridging Biosciences 等公司提供高純度和濃縮的 PRP，可以客製化以確保組織癒合和細胞再生的一致性。位於德州的美國醫學研究所提供 PRP TruDose 療法，可為各種慢性疼痛狀況提供個人化治療劑量，包括肌肉骨骼問題、紅斑性狼瘡、食物敏感性、萊姆病和其他退化性疾病。

策略性洞察報告細分和範圍基於類型的洞察血漿療法市場按類型分為純PRP、富白血球PRP、純富血小板纖維蛋白和富白血球纖維蛋白。純富血小板纖維蛋白細分市場在2022年佔據最大市場佔有率，預計在2022年至2030年期間將呈現最高複合年成長率。富白血球PRP (LR-PRP) 的中性粒細胞（白血球）濃度高於基線水平，通常與促發炎作用相關。然而，LR-PRP 也可能有助於刺激炎症，從而提示肌腱病等慢性疾病。

基於來源的洞察血漿治療市場分為自體來源和異體來源，其中自體來源在 2020 年引領市場。

基於應用的洞察：按應用細分，血漿治療市場可分為骨科疾病、皮膚科疾病、牙科疾病及其他疾病。 2022年，皮膚科疾病佔了最大的市場。

基於終端用戶的洞察：就終端用戶而言，血漿治療市場分為醫院和診所、研究機構、門診手術中心 (ASC) 和其他。醫院細分市場在 2022 年佔據最大市場佔有率，預計在 2022 年至 2030 年期間將實現最高複合年成長率。

血漿治療市場報告範圍區域分析

2022年，北美引領血漿療法市場，預計在2022年至2030年期間將創下最高複合年成長率。北美市場分為美國、加拿大和墨西哥，其中美國佔據全球血漿療法市場的最大佔有率。該地區的成長動力包括：骨科和美容手術中富血小板血漿 (PRP) 的日益普及、醫療保健領域投資的不斷增加、充滿活力的研發環境以及美國食品藥物管理局 (FDA) 對部分 PRP 療法的批准。

該報告介紹了全球血漿治療市場的關鍵參與者，包括 BioLife Plasma Services、武田藥品工業株式會社、Biotest AG CSL Ltd.、Grifols, SA、Kedrion SpA、ImmunoTek Bio Centers、Bio Products Laboratory Ltd.、中國生物製品控股公司、Octapharma AG 和 Origin, Inc.。這些領先公司專注於擴大和多樣化其市場影響力和客戶群，以利用現有的商業機會。

主要市場參與者的關鍵發展：2023 年 3 月，BioLife Plasma Services 宣佈在西斯普林菲爾德（馬薩諸塞州）和皮爾蘭（德克薩斯州）開設新的血漿捐贈中心，以增強其業務網路。 2021 年 2 月，Atlas Health Medical Group 推出了 SkinPen，這是一種結合 PRP 進行臉部拉皮的微針設備，可刺穿皮膚以刺激抗衰老反應。 2020 年 3 月，武田藥品工業株式會社開始開發抗 SARS-CoV-2 多克隆高免疫球蛋白 (H-Ig)，用於治療重症 COVID-19 患者。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第13章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 14 章：競爭格局

關鍵參與者的熱圖分析
公司定位與集中度

第 15 章：血漿療法市場 - 主要公司簡介

BioLife Plasma Services
Takeda Pharmaceutical Company Limited
Biotest AG
CSL Ltd.
Grifols, S.A.
Kedrion S.p.A
ImmunoTek Bio Centers
Bio Products Laboratory Ltd.
China Biologic Products Holdings, Inc.
Octapharma AG
Origin, Inc.

第 16 章：附錄

簡介目錄

Product Code: TIPRE00004429

The plasma therapy market is projected to expand from US$ 540.17 million in 2024 to US$ 1,308.43 million by 2031, with an estimated CAGR of 13.80% from 2025 to 2031.

Analyst's Perspective

The analysis of the plasma therapy market highlights key growth factors such as the increasing prevalence of orthopedic disorders, particularly among the elderly; a rise in joint and muscle injuries among athletes; and a growing demand for minimally invasive cosmetic treatments. Additionally, the ability to customize plasma therapies to meet individual patient needs is anticipated to create new trends in the market from 2022 to 2030.

Plasma therapy, also known as platelet-rich plasma (PRP) therapy, involves using blood plasma from individuals who have recovered from an illness to treat various medical conditions and promote healing. PRP treatments are utilized in orthopedics for joint injuries, in dermatology for skin rejuvenation, and in dentistry for tissue repair. The growth factors found in PRP effectively stimulate tissue regeneration, speeding up injury healing and enhancing aesthetic procedures.

Market Insights

Increasing Incidence of Orthopedic Disorders & Muscle Injuries and Growing Use of PRP in Aesthetic Treatments Drive Plasma Therapy MarketAccording to data from the World Health Organization (WHO) published in 2023, approximately 528 million people worldwide were living with osteoarthritis (OA) in 2019, marking a 113% increase since 1990. A December 2020 article in PubMed Central indicates that PRP has significant potential for tissue repair due to its rich content of growth factors and cytokines, which are essential for creating and regulating regenerative environments for both soft and hard tissues. PRP therapy can aid in the healing of bone fractures, ligament, muscle, and tendon injuries, peripheral nerve injuries, articular cartilage lesions, and osteoarthritis. Consequently, there is a strong demand for plasma therapies in orthopedic and tissue repair applications.

Furthermore, PRP is increasingly used in cosmetic procedures for skin rejuvenation, anti-aging, and other aesthetic applications. A review published in PubMed Central in November 2021 evaluated 73 studies, with 45 focusing on PRP monotherapy and 35 examining the effects of PRP combined with microneedling. The therapies were generally well-tolerated and effective across various skin types. Positive outcomes were reported for conditions such as skin rejuvenation, scar revision, alopecia, pigmentary disorders, lichen sclerosus, leprosy-induced peripheral neuropathy, plaque psoriasis, and nail disorders.

Thus, the application of PRP in cosmetic procedures significantly contributes to the growth of the plasma therapy market.

Future Trends

Emergence of Customization Options for Patient-Centric Therapies in the Plasma Therapy Market

Customized plasma therapy involves tailoring treatments to meet the specific needs of patients based on their medical conditions and genetic profiles. These customization efforts aim to enhance the effectiveness of plasma therapy by adjusting the composition of components like antibodies and proteins to better address the patient's health issues. Researchers and healthcare professionals are working to develop tailored plasma therapies for specific conditions such as autoimmune disorders, infectious diseases, and rare cancers. Companies like Regenexx and Bridging Biosciences offer highly pure and concentrated PRP that can be customized to ensure consistency in tissue healing and cell regeneration. The USA Medical Research Institute in Texas provides PRP TruDose therapy, which delivers personalized therapeutic doses for various chronic pain conditions, including musculoskeletal issues, LUPUS, food sensitivities, Lyme disease, and other degenerative diseases.

Strategic Insights

Report Segmentation and ScopeType-Based Insights

The plasma therapy market is categorized by type into pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin, and leukocyte-rich fibrin. The pure platelet-rich fibrin segment held the largest market share in 2022 and is expected to exhibit the highest CAGR from 2022 to 2030. Leukocyte-rich PRP (LR-PRP) contains a higher concentration of neutrophils (white blood cells) than the baseline level and is often associated with pro-inflammatory effects. However, LR-PRP can also be beneficial in stimulating inflammation to indicate chronic conditions like tendinopathy.

Source-Based Insights

The plasma therapy market is divided into autologous and allogeneic sources, with the autologous segment leading the market in 2020.

Application-Based Insights

By application, the plasma therapy market is segmented into orthopedic conditions, dermatology, dental issues, and others. The dermatology segment accounted for the largest market share in 2022.

End User-Based Insights

In terms of end users, the plasma therapy market is classified into hospitals and clinics, research institutes, ambulatory surgical centers (ASCs), and others. The hospital segment held the largest market share in 2022 and is projected to achieve the highest CAGR from 2022 to 2030.

Plasma Therapy Market Report Scope Regional Analysis

North America led the plasma therapy market in 2022 and is expected to record the highest CAGR during 2022 to 2030. The North American market is segmented into the US, Canada, and Mexico, with the US holding the largest share of the global plasma therapy market. The growth in this region is driven by the increasing adoption of platelet-rich plasma (PRP) in orthopedic and cosmetic surgeries, rising investments in healthcare, a dynamic research and development environment, and USFDA approvals for select PRP therapies.

The report profiles key players in the global plasma therapy market, including BioLife Plasma Services, Takeda Pharmaceutical Company Limited, Biotest AG CSL Ltd., Grifols, S.A., Kedrion S.p.A, ImmunoTek Bio Centers, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Octapharma AG, and Origin, Inc. These leading companies are focused on expanding and diversifying their market presence and client base to capitalize on existing business opportunities.

Key Developments by Major Market Players:In March 2023, BioLife Plasma Services announced the opening of new plasma donation centers in West Springfield (Massachusetts) and Pearland (Texas), enhancing its business network.In February 2021, Atlas Health Medical Group introduced the SkinPen, a microneedling device that incorporates PRP for facelifts, which punctures the skin to stimulate an anti-aging response.In March 2020, Takeda Pharmaceutical Company Limited began developing an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-Ig) to treat patients with severe COVID-19.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Plasma Therapy Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Plasma Therapy Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Plasma Therapy Market - Global Market Analysis

6.1 Plasma Therapy - Global Market Overview
6.2 Plasma Therapy - Global Market and Forecast to 2030

7. Plasma Therapy Market - Revenue Analysis (USD Million) - By Type, 2020-2030

7.1 Overview
7.2 Pure PRP
7.3 Leukocyte-Rich PRP
7.4 Pure Platelet-Rich Fibrin
7.5 Leukocyte-Rich Fibrin

8. Plasma Therapy Market - Revenue Analysis (USD Million) - By Source, 2020-2030

8.1 Overview
8.2 Autologous
8.3 Allogenic

9. Plasma Therapy Market - Revenue Analysis (USD Million) - By Application, 2020-2030

9.1 Overview
9.2 Orthopedic
9.3 Dermatology
9.4 Cardiac Muscle Injury
9.5 Dental
9.6 Nerve Injury
9.7 Others

10. Plasma Therapy Market - Revenue Analysis (USD Million) - By End Products Produce , 2020-2030

10.1 Overview
10.2 Albumin
10.3 Immunoglobulin G (IgG)
10.4 Others

11. Plasma Therapy Market - Revenue Analysis (USD Million) - By End User, 2020-2030

11.1 Overview
11.2 Hospitals and Clinics
11.3 Research Institutes
11.4 Ambulatory Surgical Centers

12. Plasma Therapy Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

12.1 North America
- 12.1.1 North America Plasma Therapy Market Overview
- 12.1.2 North America Plasma Therapy Market Revenue and Forecasts to 2030
- 12.1.3 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Type
- 12.1.4 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Source
- 12.1.5 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Application
- 12.1.6 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By End Products Produce
- 12.1.7 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By End User
- 12.1.8 North America Plasma Therapy Market Revenue and Forecasts and Analysis - By Countries
  - 12.1.8.1 United States Plasma Therapy Market
    - 12.1.8.1.1 United States Plasma Therapy Market, by Type
    - 12.1.8.1.2 United States Plasma Therapy Market, by Source
    - 12.1.8.1.3 United States Plasma Therapy Market, by Application
    - 12.1.8.1.4 United States Plasma Therapy Market, by End Products Produce
    - 12.1.8.1.5 United States Plasma Therapy Market, by End User
  - 12.1.8.2 Canada Plasma Therapy Market
    - 12.1.8.2.1 Canada Plasma Therapy Market, by Type
    - 12.1.8.2.2 Canada Plasma Therapy Market, by Source
    - 12.1.8.2.3 Canada Plasma Therapy Market, by Application
    - 12.1.8.2.4 Canada Plasma Therapy Market, by End Products Produce
    - 12.1.8.2.5 Canada Plasma Therapy Market, by End User
  - 12.1.8.3 Mexico Plasma Therapy Market
    - 12.1.8.3.1 Mexico Plasma Therapy Market, by Type
    - 12.1.8.3.2 Mexico Plasma Therapy Market, by Source
    - 12.1.8.3.3 Mexico Plasma Therapy Market, by Application
    - 12.1.8.3.4 Mexico Plasma Therapy Market, by End Products Produce
    - 12.1.8.3.5 Mexico Plasma Therapy Market, by End User
12.2 Europe
- 12.2.1 Germany
- 12.2.2 France
- 12.2.3 Italy
- 12.2.4 Spain
- 12.2.5 United Kingdom
- 12.2.6 Rest of Europe
12.3 Asia-Pacific
- 12.3.1 Australia
- 12.3.2 China
- 12.3.3 India
- 12.3.4 Japan
- 12.3.5 South Korea
- 12.3.6 Rest of Asia-Pacific
12.4 Middle East and Africa
- 12.4.1 South Africa
- 12.4.2 Saudi Arabia
- 12.4.3 U.A.E
- 12.4.4 Rest of Middle East and Africa
12.5 South and Central America
- 12.5.1 Brazil
- 12.5.2 Argentina
- 12.5.3 Rest of South and Central America

13. Industry Landscape

13.1 Mergers and Acquisitions
13.2 Agreements, Collaborations, Joint Ventures
13.3 New Product Launches
13.4 Expansions and Other Strategic Developments

14. Competitive Landscape

14.1 Heat Map Analysis by Key Players
14.2 Company Positioning and Concentration

15. Plasma Therapy Market - Key Company Profiles

15.1 BioLife Plasma Services
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
15.2 Takeda Pharmaceutical Company Limited
15.3 Biotest AG
15.4 CSL Ltd.
15.5 Grifols, S.A.
15.6 Kedrion S.p.A
15.7 ImmunoTek Bio Centers
15.8 Bio Products Laboratory Ltd.
15.9 China Biologic Products Holdings, Inc.
15.10 Octapharma AG
15.11 Origin, Inc.